Navigation Links
Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
Date:5/31/2012

RARITAN, N.J., May 31, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.

The kidneys of people with type 2 diabetes reabsorb greater amounts of glucose back into the body compared to non-diabetic people, which may contribute to elevated glucose levels. Canagliflozin blocks the reabsorption of glucose by the kidney, increasing glucose excretion and lowering blood glucose levels.

The filing is supported by a comprehensive global Phase 3 clinical development program, which included nine multicenter, randomized clinical studies that enrolled approximately 10,300 patients, representing the largest late-stage development program for an investigational pharmacologic product for the treatment of patients with type 2 diabetes submitted to health authorities to date. The Phase 3 program evaluated the safety and efficacy of canagliflozin across the spectrum of type 2 diabetes and included placebo- and active comparator-controlled studies. The program also included a dedicated cardiovascular study conducted in patients who have or are at high risk for developing cardiovascular disease. Janssen will present data from the Phase 3 studies at future scientific venues, beginning with the Scientific Sessions of the American Diabetes Association in Philadelphia, in June.

Janssen and its affiliates have rights to canagliflozin through a license agreement with Mitsubishi Tanabe Pharma Corporation. Janssen Pharmaceuticals, Inc. has marketing rights in North America, South America, Europe, Middle East, Africa, Australia, New Zealand and parts of Asia.

About Type 2 Diabetes

Type 2 diabetes is a chronic co
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
2. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
3. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season
4. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research
5. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
6. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
7. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
8. The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy
9. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
10. Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
11. Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... MASON, Ohio , Dec. 23, 2014 /PRNewswire/ ... industry-leading treatment decision support to healthcare providers for ... that it has secured $30 million in equity ... Virginia C. Drosos , President and Chief ... increased clinical adoption and development of Assurex Health,s ...
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 ... plc (NASDAQ: ENDP ) (TSX: ENL), and ... announced today that they have submitted a New Drug ... U.S. Food and Drug Administration (FDA).  Buprenorphine HCl Buccal ... severe enough to require daily, around-the-clock, long-term opioid treatment ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... addition of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses ... in the United States . Reimbursement ... studied. Thorough product analyses for more than 73 SMBG ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2
... N.C., March 4, 2011 The pressure for a ... greater with organizations across the pharmaceutical sector facing pipeline ... Facing an ever-changing launch landscape, product launch leaders ... new therapies through the labyrinth of regulatory and marketplace ...
... 2011 Cardica, Inc. (Nasdaq: CRDC ) ... stapling device developed by Cardica has received CE Mark ... marking process, Cardica has obtained a Full Quality Assurance ... this certification, after successful completion of development, Cardica can ...
Cached Medicine Technology:Pharmaceutical Launch Excellence Services Delivers Market Entry Road Map 2Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 2Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 3Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 4
(Date:12/25/2014)... The click strand woven bamboo flooring ... Today, the business announces a click strand woven ... 30, 2015. , Click strand woven bamboo flooring ... a well-known brand in the bamboo industry. It ... reliable bamboo flooring supplier. , “We are happy ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 “Every three months ... market changes. A-line sweetheart evening dress will be one of ... sales manager of Yunx.co.uk says. Today, the company releases 26 ... discounts, up to 80% off. , “We are trying ... unique style with our latest designs. Along with affordable prices, ...
(Date:12/25/2014)... 2014 Recently, BellasDress has ... its wedding dresses. BellasDress has chosen their best-selling lace ... choices for the holiday season. , Now, BellasDress.com ... wedding gowns here at discount prices. The business hopes ... its website. , “All our elegant products ...
(Date:12/25/2014)... 2014 Recently, LunaDress.co.uk has updated its blog to ... accessories. Now, all of the models at LunaDress.co.uk come with big ... lifts the wedding veil can turn out to be a most ... wedding veil can always bring surprise to a wedding. On the ... to choose veils for a big day . , Going ...
(Date:12/25/2014)... Among early stage breast cancer patients who undergo chemotherapy ... will eventually develop leukemia as a result of their ... from a review of more than 20,000 breast cancer ... that the risk for developing treatment-related leukemia, though low, ... "The frequency of bone marrow cancers such as leukemia ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... last week could significantly increase the success rate of ... has indicated that rejection of animal cells and organs ... the presence of the gene alpha 1,3 galactosyl transferase. ... sugar// to the surface of pig cells, flagging them ...
... heart arteries flowing easily after angioplasty shows fantastic success ... the common procedure.Doctors released the longest follow up ... testing on 30 patients over three years, they found ... unheard of in medicine.// ,More than 1 million ...
... Using modern brain imaging techniques, scientists have indicated the ... are going to be stored or deleted. The study ... of Technology (MIT) and reported to the American Association ... ,The researchers coupled a number of different ...
... more precise predictions of a person's risk of a fatal ... journal suggested the test, which measures levels of the protein ... trouble than traditional cholesterol tests and may one day lead ... of the strongest risk factors for developing coronary artery disease ...
... will probably have to depend on current anthrax vaccines ... Second-generation vaccines are in the works but not ready. ... to go, approved by the FDA.// ,The government ... anthrax vaccine to resume shipping after four years in ...
... lines could aggregate genetic abnormalities over time and new ... Dr.Vogelstein, chairman of a key stem cell research committee ... the current stem cell lines are problematic because ... cell divide in a tissue culture it accumulates mutations. ...
Cached Medicine News:Health News:Xenotransplantation “breakthrough” 2Health News:A ray of hope in Angioplasty dilemma 2Health News:Blood Test May help Heart Prediction 2Health News:New Stem Cells lines will be required 2
... Topcon, leader in the ... the most advanced technology ... conveniences and totally reliable ... Refractometry and Auto Kerato-Refractometry. ...
... Highly accurate measurement combined with short examination ... the RC-5000 both professional and quick. The ... refraction and keratometry automatically with one simple movement. ... the RC-5000 will do both eyes automatically. ...
... The Worlds First Combination Unit, the ... Refractor, Keratometer, and Non-Contact Tonometer. By combining ... allows you to save time while providing ... trust from Marco. The M3 not only ...
Designed for everyone working on clinical services, providing a streamlined, well-organized source of clinically relevant medical information....
Medicine Products: